Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%
04/09/2025
Stephanie Holland
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up...
04/09/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Stephanie Holland
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
First-Line Mobocertinib Fails to Improve Efficacy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer
03/06/2025
Stephanie Holland
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
First-Line Prolgolimab Plus Chemotherapy Improves Survival for Advanced Non-Squamous Non-Small Cell Lung Cancer
02/25/2025
Stephanie Holland
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
Telisotuzumab Vedotin Plus Osimertinib Demonstrates Promise for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer With C-Met Overexpression
02/13/2025
Stephanie Holland
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
Datopotamab Deruxtecan Shows Promise for Heavily Pretreated Patients With Advanced Non-Small Cell Lung Cancer With Actionable Mutations
01/30/2025
Stephanie Holland
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Stephanie Holland
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology

News

News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%
04/09/2025
Stephanie Holland
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up...
04/09/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Stephanie Holland
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
First-Line Mobocertinib Fails to Improve Efficacy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer
03/06/2025
Stephanie Holland
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
First-Line Prolgolimab Plus Chemotherapy Improves Survival for Advanced Non-Squamous Non-Small Cell Lung Cancer
02/25/2025
Stephanie Holland
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
Telisotuzumab Vedotin Plus Osimertinib Demonstrates Promise for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer With C-Met Overexpression
02/13/2025
Stephanie Holland
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
Datopotamab Deruxtecan Shows Promise for Heavily Pretreated Patients With Advanced Non-Small Cell Lung Cancer With Actionable Mutations
01/30/2025
Stephanie Holland
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%
04/09/2025
Stephanie Holland
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up...
04/09/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Stephanie Holland
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
First-Line Mobocertinib Fails to Improve Efficacy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer
03/06/2025
Stephanie Holland
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
First-Line Prolgolimab Plus Chemotherapy Improves Survival for Advanced Non-Squamous Non-Small Cell Lung Cancer
02/25/2025
Stephanie Holland
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
Telisotuzumab Vedotin Plus Osimertinib Demonstrates Promise for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer With C-Met Overexpression
02/13/2025
Stephanie Holland
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
Datopotamab Deruxtecan Shows Promise for Heavily Pretreated Patients With Advanced Non-Small Cell Lung Cancer With Actionable Mutations
01/30/2025
Stephanie Holland
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
FDA Approval
FDA Approves Penpulimab for Patients With Non-Keratinizing Nasopharyngeal Carcinoma
04/24/2025
Stephanie Holland
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has...
04/24/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
News
Palbociclib Plus Endocrine Therapy May Prolong Progression-Free Survival for Premenopausal Patients With HR-Positive, HER2-Negative Breast Cancer
04/23/2025
Stephanie Holland
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up...
04/23/2025
Oncology
News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
Temozolomide as Potential Second-Line Option for Patients With Small Cell Lung Cancer
04/21/2025
Stephanie Holland
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a...
04/21/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use